Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK).
Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected technology and platform.
Our primary focus is the discovery and early development of new medicines originating from its proprietary G Protein-Coupled Receptor (GPCR)-targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities. The company is advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.
Our Company has established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.
Sosei Heptares has approximately 161 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.
We are currently looking to strengthen our Molecular Pharmacology team and are seeking to recruit a highly motivated laboratory-based in vitro pharmacologist to join our team at Scientist or Research Scientist level (depending on experience).
The Molecular Pharmacology team is responsible for both new drug target validation and supporting all drug discovery phases up to pre-clinical candidate (PCC) selection via performing assays to study pathological characteristics of GPCRs in disease.
This role will primarily involve assay development and provision of routine small/large molecule screening. In addition, you may be expected to set up and run more complex mechanism of action studies in native cellular systems.
The successful candidate is expected to have:
The successful candidate will be employed by Heptares Therapeutics Ltd, a UK wholly owned subsidiary of Sosei Group Corporation.
Applicants for Scientist level must be able to demonstrate proof of the right to work in the United Kingdom.
We offer a competitive salary, commensurate with qualifications and experience, and benefits package including pension and healthcare schemes.
Applications should include a covering letter, providing a short description of the background to their interest in the role, with curriculum vitae including the names and contact details for two referees. Please apply through our on-line job’s portal with your application in pdf format, quoting reference number 2021-1MP.
The closing date for applications is 31st May 2021
Sosei Heptares does not accept speculative or unsolicited CVs from agencies. All speculative or unsolicited CVs submitted without an agreement in place will be considered Sosei Heptares's property and will not obligate us to pay a referral fee.